



ISSN NO. 2320-5407

Journal homepage: <http://www.journalijar.com>

INTERNATIONAL JOURNAL  
OF ADVANCED RESEARCH

## RESEARCH ARTICLE

### Volume Transmission in the Pathophysiology of Delirium

Adonis Sfera MD, Carolina Osorio MD

#### Manuscript Info

##### Manuscript History:

Received: 15 January 2015  
Final Accepted: 26 February 2015  
Published Online: March 2015

##### \*Corresponding Author

Adonis Sfera MD

#### ABSTRACT:

Delirium is a neurobehavioral syndrome marked by disturbances in cognition, attention, memory, perception and sleep-wake cycle which is common in hospitalized elderly. Although it is one of the oldest conditions known to medicine, its pathophysiology remains poorly understood. Since currently there are no preventive therapies for delirium, elucidation of cellular and molecular underpinnings of this condition may lead to the development of early interventions and thus prevent permanent neurologic damage.

Phylogenetically, many neurotransmitters relevant to modern neurology and psychiatry have been present in primitive organisms prior to the existence of a nervous system. Ontogenetically, several neurotransmitters, including acetylcholine, are present before synaptogenesis or neurogenesis, suggesting an alternative communication platform than synaptic transmission.

In this article we make the case for the role of volume transmission in the CNS physiology and pathology. This is a signaling modality which engenders a slower but widespread type of information processing, different than the quick point-to-point synaptic-based one. Volume transmission may be responsible for mass-sustained signaling which engenders the states of awareness, cognition or wakefulness, known to “wax and wane” in delirium. Understanding, therefore volume transmission and the information processing fathomed by it may lead us to a better grasp on the pathophysiology of this condition.

Copy Right, IJAR, 2015,. All rights reserved

## INTRODUCTION

Volume transmission (VT) represents a non-synaptic mode of intercellular signaling in the CNS in which the transfer of information is mediated by diffusion of neurotransmitters through the extracellular space (ECS). The journey of signaling molecules through the brain parenchyma is dependent on the expression of aquaporin-4 (AQP-4) water channels on astrocytic membranes and the geometry of the ECS.

VT is relevant to delirium because, unlike synaptic communication, it is as low and wide spread signaling platform better suited for pervasive CNS functions such as arousal, attention, mood, cognition and circadian rhythm. These functions are often impaired in delirium. In addition, most neurotransmitters believed to be affected in delirium, such as monoamines, acetylcholine, glutamate, endogenous opioids, GABA, as well as chemokines and cytokines are volume transmitters.

Neuroinflammation, a possible pathoetiological mechanism of delirium, is characterized by excessive glutamate release in the ECS and astrocyte edema at the expense of the ECS volume (1). Reduced ECS impairs VT of multiple neurotransmitter systems, possibly resulting in symptoms of delirium. Erythropoietin (EPO)

was shown to reverse the toxic effects of glutamate in the ECS by down-regulating AQP-4 receptors, decreasing astrocytic edema, and normalizing the ECS fluid homeostasis. Nonerythropoietic variant of EPO, such as asialoerythropoietin, may prove to be a valuable therapeutic addition to the armamentarium of delirium therapies.

### Volume or wired transmission: the soups or the sparks

Whether neurons communicate with one another electrically (sparks) or chemically (soups) was a matter of fierce debate in the early 1900s. In 1921, with Otto Loewi's discovery of the "Vagusstoff" (later named acetylcholine), the concept of the neurotransmitter was born (2). By the 1980s it became clear that not only neurons, but all CNS cells communicate with each other by releasing signaling molecules into the ECS of the brain. This gave birth to the concept of volume transmission (VT) (3).

VT was described as a communication platform among brain cells in which signaling molecules diffuse through the ECS with the flow of the interstitial fluid (ISF) and/or cerebrospinal fluid (CSF) to act upon non-synaptic receptors situated at a distance from the source of the signal (3). This concept received limited attention in psychiatry in spite of the fact that most neurotransmitters relevant to neuropsychiatric disorders, including monoamines, acetylcholine (4), glutamate (5), endogenous opioids (6), GABA (7), as well as chemokines and cytokines (8) are known volume transmitters.

In the past three decades, clinical and preclinical studies have demonstrated that in addition to synaptic or wired transmission (WT), occurring among neuronal populations, the brain cells such as glia, endothelial cells of microvessels and pericytes communicate with each other and with the neurons by releasing signaling molecules into the ECS, a common mode of communication among cells throughout most body tissues.

The two modes of communication in the CNS, WT and VT, present with different signaling characteristics. WT enables fast, selective and focused CNS functions, such as those required for playing piano, practicing sports, or driving a vehicle (9)(10). On the other hand, signaling by VT is temporally slower, broader in reach, affecting large volumes of brain tissue in a widespread manner (9)(10). This mode of signaling is better suited for enabling pervasive and mass-sustained brain functions such as arousal, attention, cognition, mood, appetite, and circadian rhythm (11). Interestingly, these are also the CNS functions affected in delirium.

VT is made possible by the circulation of ECS fluid via AQP-4 water channels expressed on perivascular astrocytic end-feet. The flow of CSF and ISF facilitates both the diffusion of neurotransmitters through the brain parenchyma and the clearance of molecular waste, such as beta amyloid and other misfolded proteins. Down-regulation of AQP-4 receptors on astrocytes predisposes to the pericellular accumulation of fluid and ECS swelling. Up-regulation of AQP-4 receptors facilitates the fluid entry into the astrocytes, causing astrocytic edema and ECS shrinking (12). A desiccated ECS with loss of fluid flow facilitates stagnation and accumulation of molecular waste which may predispose to neuroinflammation. Adequate expression of AQP-4 channels on astrocytic end-feet is essential for two functions: lowering the susceptibility to neuroinflammation and enabling physiological fluid fluctuations during sleep and wakefulness (13)(14). Recent studies demonstrated that up-regulation of AQP-4 receptors induces a pro-inflammatory state, manifested by astrocytosis and microgliosis as well as impairment of fluid homeostasis (15)(16).

A body of evidence going as far back as 1980 demonstrates that the ECS fluid volume fluctuates with the level of neuronal activity. For example, during information processing (usually during the day) the ECS decreases in size, as the fluid is pumped out. During sleep, the CSF gushes in via AQP-4 receptors, swelling the ECS. This tidal wave of ECS fluid washes the molecular waste produced by the synaptic activity throughout the previous interval of wakefulness (17)(18)(19). The circadian pattern of signaling by VT reflected in the daily fluctuations of the ECS volume may engender human chronobiological rhythms, such as arousal, attention, cognition or mood. Pathological variations of ECS volume with accompanying patterns of signaling (in neurotransmitter systems utilizing VT) may manifest clinically as fluctuations in the level of awareness frequently seen in delirium.

Table 1. Extracellular space volume and fluid circulation

Increased ECS volume	Decreased astrocytic volume	Sleep, clearance of molecular waste	Down-regulation of AQP-4 receptors	Anti-inflammatory state
Decreased ECS volume	Increased astrocytic volume	Wakefulness, accumulation of molecular waste	Up-regulation of AQP-4 receptors	Pro-inflammatory state

## Volume transmitters and delirium

Receptor mapping evidence obtained over the past three decades, utilizing autoradiography and immunochemistry demonstrates that some neurotransmitter systems signal almost exclusively via VT, while others utilize both WT and VT (20)(9). It was suggested that WT and VT may be complementary modes of cellular communication and that cellular networks may switch from one to the other depending on the type of information processing they engage in (21).

The importance of acetylcholine (ACh) in delirium was extensively documented by multiple studies, however the role of acetylcholine volumetric transmission in this disorder has been emphasized less often even though 86–93% of the cholinergic boutons in the CNS do not make synaptic contact, releasing ACh directly into the ECS (4)(9). Until recently it was believed that the diffusion of this neurotransmitter to distant non-synaptic targets was unlikely because of the presence of ACh-degrading enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the ECS. Recently, however a study demonstrated that ACh could diffuse to considerable extracellular distances in spite of AChE and BuChE because of the high extracellular concentrations of ACh-synthesizing enzyme, choline-acetyltransferase (ChAT). This enzyme is able to manufacture ACh locally, thus enabling its long distance VT at physiological ECS concentrations of AChE and BuChE (22).

Glycine and glutamate neurotransmitter systems were demonstrated to utilize both, VT and WT signaling (5)(23). The study of glutamate dynamics in the ECS was made possible by the recent development of fluorescent visualization techniques. With the help of these novel tools it was learned that the ECS glutamate originates either from synaptic spill-over or from release by the astrocytes (24). In the ECS, glutamate acts upon non-synaptic ionotropic receptors (AMPA, kainate and NMDA) and type I mGluRs (25). Non-synaptic GluRs were found to play a key role in dendritic information processing, suggesting that glutamate VT is essential for the CNS computation (26)(27). Glutamate may be crucial to the development of delirium because it achieves high extracellular concentrations during neuroinflammation. Chemokines produced by macrophages migrating into the CNS trigger glutamate release into the ECS along with up-regulation of AQP-4 receptors on astrocytic end-feet, resulting in astrocytic edema and desiccation of the ECS, possibly engendering delirium-like symptoms (1).

Monoamines are released in the ECS to diffuse with the flow of fluid to distant targets (27). Preclinical studies demonstrate that 94% of tyrosine hydroxylase-positive boutons in area 10 of the prefrontal cortex have no identifiable synaptic structures (28). Interestingly, NE signaling by VT facilitates the circadian ejection of fluid from the ECS, during wakefulness. In a recent study, mice treated with NE blockers showed both, signs of sleepiness and increased ECS fluid volume, on MRI, suggesting a direct relationship between NE modulation of the ECS volume and the physiology of sleep (15).

GABA is released by astrocytes into the ECS via bestrophin 1 channels (29)(30). The pathology of GABA VT may become clinically manifest when the ECS fluid volume is reduced, resulting in high extracellular concentration of this neurotransmitter. This may explain the hypersensitivity of delirium patients to the effects of GABA-ergic drugs.

Pro-inflammatory cytokines such as interleukin 1 beta and tumor necrosis factor alpha are produced by the reactive astrocytes and microglia. These cytokines are exclusive volume transmitters with documented involvement in sleep physiology and the pathology of neuroinflammation (31)(32).

Beta-endorphin's long distanced diffusion along with the flow of ISF and CSF was established by multiple studies (33)(34)(35). This neurotransmitter was shown to modulate widespread CNS functions such as arousal, feeding, learning, sexual behavior, pain and reward (25)(10). A reduction of the ECS fluid volume may result in excessive levels of beta-endorphins, perhaps manifested clinically as fluctuating confusion. A recent study found increased circulating levels of beta-endorphin and cortisol in postoperative delirium (36).

### **A pathophysiological model of delirium: go-with-the-flow toxicity hypothesis**

We hypothesize that reduced ECS volume results in high extracellular concentrations of molecular waste products and diffusing neurotransmitters. Both may result in delirium by impairing signaling by VT in neurotransmitter systems which engender widespread and pervasive CNS functions such as arousal, attention, mood, cognition and circadian rhythm. We hypothesize further that exogenously administered drugs may interact with the highly concentrated volume transmitters in the reduced ECS, resulting in agonistic or toxic effects manifested clinically as delirium.

Following is a proposed stepwise pathophysiological model of delirium triggered by the peripheral inflammation, such as infection or surgery (37), leading to neuroinflammation and impairment of signaling by VT:

1. In response to peripheral inflammation, macrophages migrate to the CNS and release chemokines (locally acting cytokines) which inhibit glutamate transporter-1 (GLT-1) protein in astrocytic end-feet, leading to elevated concentration of glutamate in the ECS (38)(39)(40).

Physiologically, the extracellular glutamate is regulated by a family of glutamate transporters, including GLT-1 and GLT-2 which are predominantly expressed on astrocytes (41). Interestingly, it was demonstrated that GLT-1 may form functional complexes with AQP-4 water channels and possibly with erythropoietin receptors (EPOR) which are also found in astrocytic end-feet (42)(43).

2. Extracellular glutamate, acting on non-synaptic GluR type I, increases water permeability of astrocytic end-feet by up-regulating AQP-4 channels, leading to astrocytic edema and neuroinflammation (44).

Neuroinflammation may be a direct result of astrocytic edema, or may be triggered by the accumulation of molecular waste in the ECS.

3. Edematous astrocytes along with neuroinflammation contribute to local cellular crowding at the expense of the ECS volume (46)(47).
4. Reduced ECS fluid volume and flow contributes to build up of large concentrations of volume transmitters, such as dopamine, NE, GABA, beta endorphin, cytokines or cortisol as well as molecular waste, like improperly folded proteins, impairing VT of multiple neurotransmitter systems, resulting in the fluctuating symptoms of delirium (45).

The concept of VT in the context of reduced ECS fluid volume may change the way we think about the action of drugs in delirium. After crossing the blood-brain-barrier, most pharmacological compounds diffuse throughout the ECS and readily access non-synaptic receptors. These receptors are not only more numerous than the synaptic ones, but they were demonstrated to have higher affinity for ligands, leading to the suggestion that psychotropic drugs may not reach synaptic receptors at all, but exert their action on non-synaptic receptors exclusively (25).

Under pathological circumstances of low ECS volume and high concentrations of volume transmitters (such as inflammation or ischemia), the exogenously administered drugs may interact in the ECS with diffusing agonistic neurotransmitters, resulting in additive adverse effects or toxicity, which may manifest as symptoms of delirium. This mechanism may explain, for example, delirium induced by low lithium levels frequently seen in elderly ill patients. Other examples may include the ECS interaction between benzodiazepines and the volume transmitter GABA, engendering confusion, or opiate drugs and the endogenous volume transmitter beta-endorphin, causing various degrees of lethargy.

Extensive literature exists about dopaminergic drugs, lithium, opiates and benzodiazepines predisposing to delirium (48), however the fact that they may reach high concentrations in the desiccated ECS and interact there with diffusing agonistic neurotransmitters was, perhaps given less thought.

### **Erythropoietin and aquaporins: of blood and water**

Erythropoietin (EPO) is a hematopoietic growth factor produced in the kidney and fetal liver. EPO is also produced in the CNS as a cytokine released by various non-neuronal cells into the ECS where it diffuses with the fluid flow. Over the past decade, EPO was found to have neuroprotective properties dependent on gene activation which are completely independent from its erythroid effects (49). In the past few years an immediate action of EPO, independent of gene activation, and unrelated to neuroprotection was demonstrated. It consists of blocking extra-synaptic type I mGluRs, preventing AQP-4 up-regulation. This action is triggered by EPO binding to erythropoietin receptors (EPOR) on astrocytic end-feet with the immediate effect of restoring fluid homeostasis in the ECS (50)(51). The anti-inflammatory action of EPO is twofold: direct, related to lowering extracellular glutamate, and indirect by down-regulation of AQP-4 receptors and reduction of astrocytic edema. Both pathways block reactive astrocytosis and microgliosis, and inhibit the pro-inflammatory cytokines (demonstrated by blocking lipopolysaccharide induced cytotoxicity) (52).

Recombinant human erythropoietin was found to be therapeutic in several CNS disorders including ischemic stroke, mechanical trauma, experimental autoimmune encephalitis, subarachnoid hemorrhage,

seizure disorder and neurodegenerative disorders. A recent study in rats documented that if administered systemically up to 3 hours after cerebral arterial occlusion, EPO reduces infarction volume by 75% (53).

The safety of human recombinant erythropoietin was demonstrated by more than a decade of widespread clinical use and preclinical investigations (54)(55). To our knowledge, EPO or nonerythropoietic variants of EPO were never studied in delirium, in spite of their favorable action on extracellular glutamate and AQP-4 receptors. Nonerythropoietic variants of EPO, such as asialoerythropoietin, may be ideal candidates for clinical trials in delirium because they readily cross the blood brain barrier and lack the effects on red cell mass or platelet aggregability occasionally seen with erythropoietic variants (56).

### Conclusions

Widespread CNS functions such as arousal, attention, mood, cognition and circadian rhythm, frequently affected in delirium, are believed to be mediated by VT. Major neurotransmitter systems involved in the pathoetiology of delirium are known for their non-synaptic receptors and the ability to release signaling molecules into the ECS. Pathological reduction of the ECS fluid volume predisposes to increased concentrations of volumetric transmitters which in combination with exogenously administered agonistic drugs may lead to additive toxic effects. Understanding fluid homeostasis, neuroinflammation, and VT in the CNS may lead to implementation of better delirium prevention strategies. EPO has an established safety record, including use in newborn children. In our opinion, the ability of nonerythropoietic variants of EPO to reverse the toxic effects of glutamate in the ECS renders them optimal candidates for delirium therapy.

### References:

1. Fukuda AM, Badaut J. Aquaporin 4: A Player in Cerebral Edema and Neuroinflammation. *Journal of Neuroinflammation* (2012) 9:279 doi:10.1186/1742-2094-9-279
2. Elliot S. Valenstein. *The War of the Sops and Sparks: The Discovery of Neurotransmitters and the Dispute over How Nerves Communicate*. New York, Columbia University Press (2005). 256p.
3. Zoli M, Jansson A, Syková E, Agnati LF, Fuxe K. Volumetric transmission in the CNS and its relevance for neuropsychopharmacology. *Trends Pharmacol Sci.* (1999) (4):142-50.
4. Lendvai B, E. Vizi S. Nonsynaptic Chemical Transmission Through Nicotinic Acetylcholine Receptors. *Physiological Reviews* (2008) Vol. 88 no. 333-349 DOI:10.1152/physrev.00040.2006
5. Okubo Y, Iino M. Visualization of glutamate as a volumetric transmitter. *J Physiol.* (2011) 589 (Pt3):481-8. doi:10.1113/jphysiol.(2010).199539.
6. Veening JG, Gerrits PO, Barendregt HP. Volumetric transmission of beta-endorphin via the cerebrospinal fluid; a review. *Fluids and Barriers of the CNS* (2012) 9:16. doi:10.1186/2045-8118-9-16

7. Trueta C, De-Miguel FF. Extrasynaptic exocytosis and its mechanisms: a source of molecules mediating volume transmission in the nervous system. *Front. Physiol.* (2012). doi:10.3389/fphys.2012.00319
8. Fuxe K, Borroto-Escuela DO, Tarakanov A, Fernandez WR, Manger P, Rivera A, van Craenenbroeck K, Skietarska K, Diaz-Cabiale Z, Malgorzata F. Understanding the balance and integration of volume and synaptic transmission. Relevance for psychiatry. *Neurology, Psychiatry and Brain Research* (2013). Volume 19, Issue 4p. 141-158.
9. Katherine H. Taber, Ph.D.; Robin A. Hurley, M.D. Volume Transmission in the Brain: Beyond the Synapse. *The Journal of Neuropsychiatry and Clinical Neurosciences* (2014) 26:iv-4. doi:10.1176/appi.neuropsych.13110351
10. Gualtieri TC. Brain Injury and Mental Retardation: Psychopharmacology and Neuropsychiatry. *Lippincott Williams & Wilkins* (2002) Philadelphia pp. 464-465
11. Vizi ES, Fekete A, Karoly R, Mike A. Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. *Br J Pharmacol.* (2010) 160(4):785-809. doi:10.1111/j.1476-5381.2009.00624.x.
12. Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. *Pediatr Nephrol.* (2007) 22(6):778-84.
13. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. *Science* (2013) 342:373-710. doi:10.1126/science.1241224
14. Yang L, Kress BT, Weber HJ, Thiyagarajan M, Wang B, Deane R, et al. Evaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer. *J Transl Med* (2013) 11(1):107. doi:10.1186/1479-5876-11-107
15. Li L, Zhang H, Varrin-Doyer M, Scott S, Verkman AS. Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation. *The FASEB Journal* (2011) vol. 25 no. 5 1556-1566. doi:10.1096/fj.10-177279
16. Aoki-Yoshino K, Uchihara T, Duyckaerts C, Nakamura A, Hauw JJ, Wakayama Y. Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. *Acta Neuropathol.* (2005) 110(3):281-8
17. Iliff JJ, Hedok L, Yu M, Feng T, Logan J, Nedergaard M, et al. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. *J Clin Invest* (2013) 123:1299-309. doi:10.1172/JCI67677
18. Dietzel I, Heinemann U, Hofmeier G. Transient changes in the size of the extracellular space in the sensorimotor cortex of cats in relation to stimulus-induced changes in potassium concentration. *Experimental Brain Research.* (1980) 40(4):432-439.
19. Haj-Yasein NN, Jensen V, Østby, Omholt SW, Voipio J, Kaila K, Ottersen OP, Hvalby Ø, Nagelhus EA. Aquaporin-4 regulates extracellular space volume dynamics during high-frequency synaptic stimulation: a gene deletion study in mouse hippocampus. *Glia* (2012) 60(6):867-74. doi:10.1002/glia.22319.

20. Agnati LF, Zoli M, Strömberg I, Fuxe K. Intercellular communication in the brain: wiring versus volumetric transmission. *Neuroscience* (1995) 69(3):711-26.
21. Zoli M, Torri C, Ferrari R, Jansson A, Zini I, Fuxe K, Agnati LF. The emergence of the volume transmission concept. *Brain Res Brain Res Rev.* (1998) 26(2-3):136-47.
22. Vijayaraghavan S, Karami A, Aeinband S, Behbahani H, Grandien A, Kristina NE, Lindblom RPF, Piehl F, Darreh-Shori T. Regulated Extracellular Choline Acetyltransferase Activity— The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway. *PLOS One* (2013) DOI:10.1371/journal.pone.0065936
23. Harsing LG Jr, Matyus P: Mechanisms of glycine release, which build up synaptic and extrasynaptic glycine levels: the role of synaptic and non-synaptic glycine transporters. *Brain Res Bull* (2013) 93:110–119
24. Okubo Y, Iino M. Visualization of glutamate as a volumetric transmitter. *J Physiol.* (2011) 589(Pt 3):481–8. doi:10.1113/jphysiol.2010.199539.
25. Vizi ES, Fekete A, Karoly R, Mike A. Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment. *Br J Pharmacol.* (2010) 160(4):785-809. doi:10.1111/j.1476-5381.2009.00624.x.
26. Camiré O, Lacaille JC, Topolnik L. Dendritic signaling in inhibitory interneurons: local tuning via group I metabotropic glutamate receptors. *Front. Physiol.* (2012) doi: 10.3389/fphys.2012.00259
27. Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, Diaz-Cabiale Z, Rivera A, Ferraro L, Tanganelli S, Tarakanov AO, Garriga P, Narváez JA, Ciruela F, Guescini M, Agnati LF. Extrasynaptic Neurotransmission in the Modulation of Brain Function. Focus on the Striatal Neuronal–Glial Networks. *Front Physiol* (2012) 3:136. doi:10.3389/fphys.2012.00136
28. Martin KA, Spühler IA: The fine structure of the dopaminergic innervation of area 10 of macaque prefrontal cortex. *Eur J Neurosci.* (2013) 37:1061–1071
29. Seonmi J, Yarishkin O, Yu J H, Ye EC, Park M, Dong H W, Bae JY, Kim T, Lee J, Chun H, Park HJ, Yong D L, Hong J, Kim HY, Oh SJ, Park SJ, Lee H, Yoon BE, Kim YS, Jeong Y, Shim I, Bae YC, J Cho J, Kowall NW, Ryu H, Hwang E, Kim D, Lee CJ. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. *Nature Medicine* (2014). doi:10.1038/nm.3639
30. Kotani N, Akaike N: The effects of volatile anesthetics on synaptic and extrasynaptic GABA-induced neurotransmission. *Brain Res Bull* (2013) 93:69–79
31. Vitkovic L, Bockaert J, Jacque C. "Inflammatory" cytokines: neuromodulators in normal brain? *J Neurochem.* (2000) 74(2):457-71.
32. van Gool WA. Brain disorders in critical illness. In: Stevens RD, Sharshar T, Wesley EE, editors. *Mechanisms, Diagnosis, and Treatment.* Cambridge: Cambridge University Press; (2013). 102p.

33. Hartung HP, Dihne M. Volume Transmission–Mediated Encephalopathies A Possible New Concept? *Arch Neurol.* (2012)69(3):315-321. doi:10.1001/archneurol.2011.933.
34. Fuxe K, Romero-Fernandez W, Wei-bo Zhang WB, Luigi F. Agnati, Borroto-Escuela DO. Volume 28 transmission and its different forms in the central nervous system. *Chinese journal of integrative medicine* (2013) Volume 19, Issue 5, pp 323-329 doi:10.1007/s11655-013-1455-1
35. Veening JG, Gerrits PO, Barendregt HP. Volume transmission of beta-endorphin via the cerebrospinal fluid; a review. *Fluids and Barriers of the CNS* (2012)9:16 doi:10.1186/2045-8118-9-16
36. McIntosh TK, Bush HL, Yeston NS, Grasberger R, Palter M, Aun F, Egdahl RH. Beta-endorphin, cortisol and postoperative delirium: a preliminary report. *Psychoneuroendocrinology.* (1985)10(3):303-13.
37. Vacas S, Degos V, Tracey KJ, Maze M. High-mobility group box 1 protein initiates postoperative cognitive decline by engaging bone marrow-derived macrophages. *Anesthesiology* (2014) 120(5):1160-7. doi:10.1097/ALN.0000000000000045
38. A Zeng XN, Sun XL, Gao L, Fan Y, Ding JH, Hu G. Aquaporin-4 deficiency down-regulates glutamate uptake and GLT-1 expression in astrocytes. *Mol Cell Neurosci.* (2007)34(1):34-9. DOI: 10.1016/j.mcn.2006.09.008
39. Li YK, Wang F, Wang W, Luo Y, Wu PF, Xiao JL, Hu ZL, Jin Y, Hu G, Chen JG. Aquaporin-4 Deficiency Impairs Synaptic Plasticity and Associative Fear Memory in the Lateral Amygdala: Involvement of Downregulation of Glutamate Transporter-1 Expression. *Neuropsychopharmacology* (2012)37, 1867–1878; doi:10.1038/npp.2012.34.
40. Fang J, Han D, Hong J, Tan Q, Tian Y. The chemokine, macrophage inflammatory protein-2 $\gamma$ , reduces the expression of glutamate transporter-1 on astrocytes and increases neuronal sensitivity to glutamate excitotoxicity. *Journal of Neuroinflammation* (2012)9:267 doi:10.1186/1742-2094-9-267
41. Gundersen GA. Roles of aquaporin-4 in brain fluid dynamics. Doctoral dissertation (2013). University of Oslo. Permanent link: <http://urn.nb.no/URN:NBN:no-35336>
42. Mogoanta L, Ciurea M, Pirici I, Margaritescu C, Simionescu C, Ion DA, Pirici D. Different Dynamics of Aquaporin 4 and Glutamate Transporter-1 Distribution in the Perineuronal and Perivascular Compartments during Ischemic Stroke. *Brain Pathol.* (2014). doi: 10.1111/bpa.12134.
43. Beart PM, O'Shea RD. Transporters for l-glutamate: an update on their molecular pharmacology and pathological involvement. *Br J Pharmacol* (2007)1505-17. doi:10.1038/sj.bjp.0706949
44. Gunnarson E, Songa Y, Kowalewski JM, H Brismara H, Brines DM, Ceramid A, Andersson U, Zelenina AM, Aperia A. Erythropoietin modulation of astrocyte water permeability as a component of neuroprotection. *PANS* (2009)106(5)1602–1607 doi:10.1073/pnas.0812708106

45. Aoki-Yoshino K, Uchihara T, Duyckaerts C, Nakamura A, Hauw JJ, Wakayama Y. Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. *Acta Neuropathol.* (2005) 110(3):281-8. DOI: 10.1007/s00401-005-1052-2
46. Syková E, Nicholson C. Diffusion in brain extracellular space. *Physiological Reviews* (2008) 88(4):1277-1340. doi: 10.1152/physrev.00027.2007.
47. Syková E. Extrasynaptic volume transmission and diffusion parameters of the extracellular space. *Neuroscience* (2004) 129(4):861-76. DOI: 10.1016/j.neuroscience.2004.06.077
48. Maldonado JR. Pathoetiological Model of Delirium: a Comprehensive Understanding of the Neurobiology of Delirium and an Evidence-Based Approach to Prevention and Treatment. *Crit Care Clin* 24(2008)789-856 DOI: 10.1016/j.ccc.2008.06.004
49. Noguchi CT, Asavaritikrai P, Teng R, Jia Y. Role of erythropoietin in the brain. *Crit Rev Oncol Hematol.* (2007) 64(2): 159-171. doi: 10.1016/j.critrevonc.2007.03.001
50. Nagelhus EA, Ottersen OP. Physiological Roles of Aquaporin-4 in Brain. *Physiol Rev.* (2013) 93(4): 1543-1562. doi: 10.1152/physrev.00011.2013
51. Tang Z, Sun X, Huo G, Xie Y, Shi Q, Chen S, Wang X, Liao Z. Protective effects of erythropoietin on astrocytic swelling after oxygen-glucose deprivation and reoxygenation: mediation through AQP4 expression and MAPK pathway. *Neuropharmacology* (2013) 67:8-15. doi: 10.1016/j.neuropharm.2012.10.017
52. Brissaud O, Villega F, Pieter-Konsman J, Sanchez S, Raffard G, Franconi JM, Chateil JF, Bouzier-Sore AK. Short-term effect of erythropoietin on brain lesions and aquaporin-4 expression in a hypoxic-ischemic neonatal rat model assessed by magnetic resonance diffusion weighted imaging and immunohistochemistry. *Pediatr Res.* (2010) 68(2):123-7. doi:10.1203/00006450-201011001-00237.
53. Anna-Leena Sirén AL, Fratelli M, Brines M, CGoemans C, S Casagrande C, Lewczuk P, Keenan S, Gleiter C, CPasquali C, Capobianco A, Mennini T, Heumann R, Cerami A, Ehrenreich H, Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. *PNAS* (2001) 98(7)4044-4049. doi:10.1073/pnas.051606598
54. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. *Nature Reviews Neuroscience* (2005) 6, 484-494 doi:10.1038/nrn1687
55. Marti HH. Erythropoietin and the hypoxic brain. *J Exp Biol.* (2004) 207, 3233-324 doi: 10.1242/jeb.01049
56. Erbayraktar S, Grasso G, Sfactoria A, Xie QW, Coleman T, Kreilgaard M, Torup L, Sager T, Erbayraktar Z, Gokmen N, Yilmaz O, Ghezzi P, Villa P, Fratelli M, Casagrande S, Leist M, Helboe L, Gerwein J, Christensen S, Geist MA, Pedersen LØ, Cerami-Hand C, Wuerth JP, Cerami A, Brines M. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. *Proc Natl Acad Sci US A.* (2003) 100(11):6741-6